PDL BioPharma pioneered the humanization of monoclonal antibodies
and, by so doing, enabled the discovery
of a new generation of targeted treatments for cancer and immunologic diseases.
PDL BioPharma to Announce Second Quarter 2015 Financial Results on August 5, 2015
PDL BioPharma Announces $40 Million Financing Transaction with CareView Communications
PDL BioPharma to Present at the Nasdaq 32nd Investor Program
PDL BioPharma Appoints Steffen Pietzke as Controller and Chief Accounting Officer
PDL BioPharma Completes Regular Quarterly Dividend Payment